GSK: 'SENKU' designation for bepirovirsen in Japan
(CercleFinance.com) - GSK announces that the Japanese Ministry of Health has granted 'SENKU' designation for bepirovirsen, an investigational treatment for chronic hepatitis B.
This designation is intended to accelerate patient access to innovative medicines to treat serious diseases.
This designation aims to accelerate patient access to innovative medicines to treat serious diseases.
It is based on promising results from Phase IIb trials, and a Phase III trial is currently underway.
Chronic hepatitis B affects 257 million people worldwide, including nearly a million in Japan, and current treatments have very low functional cure rates.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This designation is intended to accelerate patient access to innovative medicines to treat serious diseases.
This designation aims to accelerate patient access to innovative medicines to treat serious diseases.
It is based on promising results from Phase IIb trials, and a Phase III trial is currently underway.
Chronic hepatitis B affects 257 million people worldwide, including nearly a million in Japan, and current treatments have very low functional cure rates.
Copyright (c) 2024 CercleFinance.com. All rights reserved.